The Experience and Implications from Coverage with Evidence Development for Cell and Gene Therapy Products in the UK.
- VernacularTitle:英国细胞基因治疗产品基于证据发展的报销经验与启示
- Author:
Yijia QI
1
;
Luying ZHANG
1
;
Feifei CHEN
1
Author Information
1. 复旦大学公共卫生学院 上海 200032
- Publication Type:Journal Article
- Keywords:
cell and gene therapy product;
evidence development based reimbursement experience;
UK.
- From:
Chinese Health Economics
2025;44(11):104-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the experiences of implementing coverage with evidence development for cell and gene therapy products in the UK.to provide references for the future access of cell and gene therapy products in China.Methods:By systematically combing the strategies of coverage with evidence development adopted by National Health Service(NHS)in the UK.,and summarizing the four links of assessment,payment,further evidence collection and final decision-making,the implementation experience of coverage with evidence development of cell and gene therapy products was analyzed by taking the reimbursement of four typical cell gene therapy products as an example,and suggestions were made for the access of this type of products in China.Results:Access to cell and gene therapy products in the UK.is cautious,with assessment focused on clinical utility.Management access agreement is used to control the risk of overspending during specialized fund reimbursement,while a unified data collection system has been established.Conclusion:China could learn from the experience of the UK.and promote the admission of cell gene therapy products from three aspects:exploring the evidence-based reimbursement model for universal commercial medical insurance;developing a targeted data collection framework based on actual data needs;establishing a unified data collection platform to provide the support for product access decision.
